Issues

The cover of this issue of Clinical Science features images showcasing the effects of NM-FGF19 mRNA-LNPs on liver histology and lipid content. Representative histological images demonstrate a MASH phenotype with steatosis, hepatocyte ballooning, inflammatory foci, and mild fibrosis in the Control group, which is reversed to healthy-like macroscopic histology in NM-FGF19-treated mice. Read more in, ‘Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)’ from Avila, Berraondo and colleagues on pp1265–1284.